Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00327249 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

A Phase 1 study of Multiple Myeloma, sponsored by AmpliMed Corporation.

Completed
Registry status
Phase 1
Development phase
2
Study locations

NCT00327249 is a Phase 1 study of Multiple Myeloma that has completed, run by AmpliMed Corporation. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00327249, a Phase 1 study of Multiple Myeloma, has completed, sponsored by AmpliMed Corporation.

COMPLETED
Registry status
Phase 1
Development phase
2
Study locations

Study Summary

AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to provide additional safety data and to gain an understanding of whether imexon can improve the outcome for patients with multiple myeloma

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG imexon

Study Locations (2)

Arkansas

  • Investigational Site 025 - Little Rock

Texas

  • Investigational Site 008 - Houston

Trial Details

FieldValue
Start Date 2005-10
Est. Completion 2008-01
Phase Phase 1

Sponsor

AmpliMed Corporation

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00327249

The ClinicalTrials.gov registry entry for NCT00327249 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is AmpliMed Corporation, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which imexon is the first listed.

NCT00327249 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arkansas, Texas.

Frequently Asked Questions

What is clinical trial NCT00327249 about?

NCT00327249 is a clinical study titled "Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients". AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple myeloma. The first phase of the study is designed to determine a safe dose of imexon that can be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of the study is designed to ...

What is the current status of trial NCT00327249?

This trial is currently completed. It is a Phase 1 study. The study started on 2005-10. Estimated completion is 2008-01.

What conditions does trial NCT00327249 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00327249?

The interventions under investigation include: imexon (DRUG).

Who is sponsoring clinical trial NCT00327249?

This trial is sponsored by AmpliMed Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00327249 being conducted?

This trial has 2 study locations across Arkansas, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.